ESMO 2021 | CAPItello-292: capivasertib, palbociclib, and fulvestrant for HR+ endocrine-resistant breast cancer
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses CAPItello-292 (NCT04862663), a Phase Ib/III trial of capivasertib, palbociclib and fulvestrant versus palbociclib and fulvestrant for hormone receptor-positive (HR+) patients with endocrine-resistant advanced breast cancer. Dr Hamilton mentions promising results for AKT inhibitors in previous studies and highlights how this triplet combination could provide great insight. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr. Hamilton discloses research funding (payable to institution only, no personal funds) from: OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millenium, Acerta Pharma, Sermonix Pharmaceuticals, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, FujiFilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, SeaGen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, Abbvie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, Amgen, Akesobio Australia, Shattuck Labs.
D. Hamilton discloses consulting/advisory role payments (to institution only, no personal funds accepted) from: Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, AstraZeneca, Arvinas, Deciphera Pharmaceuticals, Eisai, Seagen.
